Top

Cancer Cell International

Published in:

01-12-2021 | Breast Cancer | Primary research

VWCE as a potential biomarker associated with immune infiltrates in breast cancer

Authors: Qin Huo, Zhenwei Li, Siqi Chen, Juan Wang, Jiaying Li, Ni Xie

Published in: Cancer Cell International | Issue 1/2021

Abstract

Purpose

Von Willebrand Factor C and EGF Domains (VWCE) is an important gene that regulates cell adhesion, migration, and interaction. However, the correlation between VWCE expression and immune infiltrating in breast cancer remain unclear. In this study, we investigated the correlation between VWCE expression and immune infiltration levels in breast cancer.

Methods

The expression of VWCE was analyzed by the tumor immune estimation resource (TIMER) and DriverDB databases. Furthermore, genes co-expressed with VWCE and gene ontology (GO) enrichment analysis were investigated by the STRING and Enrichr web servers. Also, we performed the single nucleotide variation (SNV), copy number variation (CNV), and pathway activity analysis through GSCALite. Subsequently, the relationship between VWCE expression and tumor immunity was analyzed by TIMER and TISIDB databases, and further verified the results using Quantitative Real-Time PCR (RT-PCR), Western blotting, and immunohistochemistry.

Results

The results showed that the expression of VWCE mRNA in breast cancer tissue was significantly lower than that in normal tissues. We found that the expression level of VWCE was associated with subtypes, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status of breast cancer patients, but there was no significant difference in the expression of VWCE was found in age and nodal status. Further analyses indicated that VWCE was correlated with the activation or inhibition of multiple oncogenic pathways. Additionally, VWCE expression was negatively correlated with the expression of STAT1 (Th1 marker, r = − 0.12, p = 6e−05), but positively correlated with the expression of MS4A4A (r = 0.28, p = 0). These results suggested that the expression of VWCE was correlated with immune infiltration levels of Th1 and M2 macrophage in breast cancer.

Conclusions

In our study, VWCE expression was associated with a better prognosis and was immune infiltration in breast cancer. These findings demonstrate that VWCE is a potential prognostic biomarker and correlated with tumor immune cell infiltration, and maybe a promising therapeutic target in breast cancer.

Available only for authorised users

Huo Q, Li Z, Cheng L, Yang F, Xie N. SIRT7 is a prognostic biomarker associated with immune infiltration in luminal breast cancer. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.00621.CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Shreedhara AK, Shanbhag S, Joseph RC, et al. A study of maternal breast feeding issues during early postnatal days. SciMed J. 2020;2(4):219–24. https://doi.org/10.28991/SciMedJ-2020-0204-4.CrossRef

Qiu N, He Y, Zhang S, Hu X, Chen M, Li H. Cullin 7 is a predictor of poor prognosis in breast cancer patients and is involved in the proliferation and invasion of breast cancer cells by regulating the cell cycle and microtubule stability. Oncol Rep. 2018;39(2):603–10. https://doi.org/10.3892/or.2017.6106.CrossRefPubMed

Baxevanis CN, Sofopoulos M, Fortis SP, Perez SA. The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. Cancer Immunol Immunother. 2019;68(10):1671–80. https://doi.org/10.1007/s00262-019-02327-7.CrossRefPubMed

Bremnes RM, Busund L-T, Kilvær TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non–small cell lung cancer. J Thorac Oncol. 2016;11(6):789–800. https://doi.org/10.1016/j.jtho.2016.01.015.CrossRefPubMed

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell. 2018;173(7):1755-1769 e1722. https://doi.org/10.1016/j.cell.2018.03.073.CrossRefPubMed

Puccetti L, Manetti R, Parronchi P, Piccinni MP, Mavilia C, Carini M, Romagnani S, Maggi E. Role of low nuclear grading of renal carcinoma cells in the functional profile of tumor-infiltrating T cells. Int J Cancer. 2002;98(5):674–81. https://doi.org/10.1002/ijc.10238.CrossRefPubMed

Lee N, Zakka LR, Mihm MC Jr, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48(2):177–87. https://doi.org/10.1016/j.pathol.2015.12.006.CrossRefPubMed

10.

Gil M, Kim KE. Interleukin-18 is a prognostic biomarker correlated with CD8+ T cell and natural killer cell infiltration in skin cutaneous melanoma. J Clin Med. 2019;8(11):1993. https://doi.org/10.3390/jcm8111993.CrossRefPubMedCentral

11.

Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4(1):59. https://doi.org/10.1186/s40425-016-0165-6.CrossRefPubMedPubMedCentral

12.

Lian Z, Liu J, Li L, Li X, Tufan NL, Clayton M, Wu MC, Wang HY, Arbuthnot P, Kew M, et al. Upregulated expression of a unique gene by hepatitis B x antigen promotes hepatocellular growth and tumorigenesis. Neoplasia. 2003;5(3):229–44. https://doi.org/10.1016/S1476-5586(03)80055-6.CrossRefPubMedPubMedCentral

13.

Peng W, Zhang J, Liu J. URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial–mesenchymal transition-driven invasion. Med Oncol. 2014;31(7):64. https://doi.org/10.1007/s12032-014-0064-y.CrossRefPubMed

14.

Du R, Xia L, Sun S, Lian Z, Zou X, Gao J, Xie H, Fan R, Song J, Li X. URG11 promotes gastric cancer growth and invasion by activation of β-catenin signalling pathway. J Cell Mol Med. 2010;14(3):621–35. https://doi.org/10.1111/j.1582-4934.2008.00622.x.CrossRefPubMed

15.

Fan R, Li X, Du W, Zou X, Du R, Zhao L, Luo G, Mo P, Xia L, Pan Y. Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma. Int J Cancer. 2011;128(12):2980–93. https://doi.org/10.1002/ijc.25624.CrossRefPubMed

16.

Sun C, Zhang G, Cheng S, Qian H, Li D, Liu M. URG11 promotes proliferation and induced apoptosis of LNCaP cells. Int J Mol Med. 2019;43(5):2075–85. https://doi.org/10.3892/ijmm.2019.4121.CrossRefPubMedPubMedCentral

17.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10. https://doi.org/10.1158/0008-5472.CAN-17-0307.CrossRefPubMedPubMedCentral

18.

Liu SH, Shen PC, Chen CY, Hsu AN, Cho YC, Lai YL, Chen FH, Li CY, Wang SC, Chen M, et al. DriverDBv3: a multi-omics database for cancer driver gene research. Nucleic Acids Res. 2020;48(D1):D863–70. https://doi.org/10.1093/nar/gkz964.CrossRefPubMed

19.

Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G, Campion L. bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2012;131(3):765–75. https://doi.org/10.1007/s10549-011-1457-7.CrossRefPubMed

20.

Crosara KTB, Moffa EB, Xiao Y, Siqueira WL. Merging in-silico and in vitro salivary protein complex partners using the STRING database: a tutorial. J Proteomics. 2018;171:87–94. https://doi.org/10.1016/j.jprot.2017.08.002.CrossRefPubMed

21.

Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90-97. https://doi.org/10.1093/nar/gkw377.CrossRefPubMedPubMedCentral

22.

Gaudet P, Škunca N, Hu JC, Dessimoz C. Primer on the gene ontology. Methods Mol Biol. 2017;1446:25–37. https://doi.org/10.1007/978-1-4939-3743-1_3.CrossRefPubMedPubMedCentral

23.

Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014;5(1):3887. https://doi.org/10.1038/ncomms4887.CrossRefPubMed

24.

Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I. TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics. 2019;35(20):4200–2. https://doi.org/10.1093/bioinformatics/btz210.CrossRefPubMed

25.

Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. https://doi.org/10.1186/s13059-016-1028-7.CrossRefPubMedPubMedCentral

26.

Zhang Y, Yuan Y, Liang P, Zhang Z, Guo X, Xia L, Zhao Y, Shu XS, Sun S, Ying Y, et al. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer. Oncotarget. 2017;8(28):45459–69. https://doi.org/10.18632/oncotarget.17564.CrossRefPubMedPubMedCentral

27.

Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X, Huang Z, Chen L, Huang Y, Huang Y. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020;12(1):784. https://doi.org/10.18632/aging.102656.CrossRef

28.

Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun. 2007;7(1):4.PubMedPubMedCentral

29.

Gou R, Zhu L, Zheng M, Guo Q, Hu Y, Li X, Liu J, Lin B. Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins. J Transl Med. 2019;17(1):275. https://doi.org/10.1186/s12967-019-2023-z.CrossRefPubMedPubMedCentral

30.

Habibeh Z. Effects of salvia officinalis extract on the breast cancer cell line. SciMedicine Journal. 2019;1(1):25–9. https://doi.org/10.28991/SciMedJ-2019-0101-4.CrossRef

31.

Gomez A, Santana PC, Mouro AP. Dosimetry study in head and neck of anthropomorphic phantoms in computed tomography scans. SciMed J. 2020;2(1):38–43. https://doi.org/10.28991/SciMedJ-2020-0201-6.CrossRef

32.

Zou X, Li X, Liu J, Lian Z, Fan R, Du R, Xie H, Song J, Fan D. Preparation and characterization of a specific monoclonal antibody against a new gene product: URG11. Hybridoma (Larchmt). 2006;25(6):378–81. https://doi.org/10.1089/hyb.2006.25.378.CrossRef

33.

Pan B, Ye Y, Liu H, Zhen J, Zhou H, Li Y, Qu L, Wu Y, Zeng C, Zhong W. URG11 regulates prostate cancer cell proliferation, migration, and invasion. Biomed Res Int. 2018;2018:4060728. https://doi.org/10.1155/2018/4060728.CrossRefPubMedPubMedCentral

34.

Tong GD, Zhang X, Zhou DQ, Wei CS, He JS, Xiao CL, Liu XL, Zheng YJ, Chen SN, Tang HH. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L. Chin J Integr Med. 2014;20(4):263–71. https://doi.org/10.1007/s11655-013-1320-7.CrossRefPubMed

35.

Liu Z-L, Wu J, Wang L-X, Yang J-F, Xiao G-M, Sun H-P, Chen Y-J. Knockdown of upregulated gene 11 (URG11) inhibits proliferation, invasion, and β-catenin expression in non-small cell lung cancer cells. Oncol Res Featur Preclin Clin Cancer Ther. 2016;24(3):197–204. https://doi.org/10.3727/096504016X14648701447850.CrossRef

36.

Song X, Liu S, Qu X, Hu Y, Zhang X, Wang T, Wei F. BMP2 and VEGF promote angiogenesis but retard terminal differentiation of osteoblasts in bone regeneration by up-regulating Id1. Acta Biochim Biophys Sin (Shanghai). 2011;43(10):796–804. https://doi.org/10.1093/abbs/gmr074.CrossRef

37.

Song J, McColl J, Camp E, Kennerley N, Mok GF, McCormick D, Grocott T, Wheeler GN, Munsterberg AE. Smad1 transcription factor integrates BMP2 and Wnt3a signals in migrating cardiac progenitor cells. Proc Natl Acad Sci USA. 2014;111(20):7337–42. https://doi.org/10.1073/pnas.1321764111.CrossRefPubMedPubMedCentral

38.

O’Neill HL, Cassidy AP, Harris OB, Cassidy JW. BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas. PeerJ. 2016;4:e1957. https://doi.org/10.7717/peerj.1957.CrossRefPubMedPubMedCentral

39.

Osmanagic-Myers S, Rezniczek GA. Arteriovenous specification: BMPER and TWSG1 determine endothelial cell fate via activation of synergistic BMP and Notch signaling. FEBS J. 2018;285(8):1399–402. https://doi.org/10.1111/febs.14439.CrossRefPubMedPubMedCentral

40.

Josephine KO, Lung ML, Chan PL, et al. Functional complementation and gene expression profile analysis identified THSD1 at 13q14 as a novel candidate tumor suppressor gene for esophageal squamous cell carcinoma doboku gakkai ronbunshuu f, 2008; 64(3):261–271. : https://doi.org/10.2208/jscejf.64.261.

41.

Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, Park JE, Rettig WJ, Lenter MC. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem. 2001;276(10):7408–14. https://doi.org/10.1074/jbc.M009604200.CrossRefPubMed

42.

Oda K, Kato K, Nakamura M, Jotatsu T, Noguchi S, Kawanami T, Kido T, Yatera K. Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab. Lung Cancer. 2018;118:171–2. https://doi.org/10.1016/j.lungcan.2018.02.012.CrossRefPubMed

43.

Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, Miyakawa A, Kobayashi J, Kaneko T, Igarashi T. Tumor-infiltrating CD8+ T cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8(1):80–93. https://doi.org/10.1002/cam4.1889.CrossRefPubMedPubMedCentral

44.

Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Lang I, Ruhstaller T, Gianni L, Goldhirsch A, et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22–00. Breast Cancer Res Treat. 2016;158(2):323–31. https://doi.org/10.1007/s10549-016-3863-3.CrossRefPubMedPubMedCentral

45.

Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017;2017:9624760. https://doi.org/10.1155/2017/9624760.CrossRefPubMedPubMedCentral

46.

Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother. 2004;53(4):275–306. https://doi.org/10.1002/eji.201970107.CrossRefPubMed

47.

Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Chng ES. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2019;9:512. https://doi.org/10.3389/fonc.2019.01512.CrossRef

48.

Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013;496:445–55. https://doi.org/10.1038/nature12034.CrossRefPubMedPubMedCentral

49.

Lieberman LA, Banica M, Reiner SL, Hunter CA. STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis. J Immunol. 2004;172(1):457–63. https://doi.org/10.4049/jimmunol.172.1.457.CrossRefPubMed

50.

Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267(2):204–15. https://doi.org/10.1016/j.canlet.2008.03.028.CrossRefPubMed

51.

Shiraishi D, Fujiwara Y, Horlad H, Saito Y, Iriki T, Tsuboki J, Cheng P, Nakagata N, Mizuta H, Bekki H. CD163 is required for protumoral activation of macrophages in human and murine sarcoma. Can Res. 2018;78(12):3255–66. https://doi.org/10.1158/0008-5472.CAN-17-2011.CrossRef

52.

Alvarado-Vazquez PA, Bernal L, Paige CA, Grosick RL, Moracho Vilrriales C, Ferreira DW, Ulecia-Moron C, Romero-Sandoval EA. Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions. Immunobiology. 2017;222(8–9):900–12. https://doi.org/10.1016/j.imbio.2017.05.011.CrossRefPubMedPubMedCentral

53.

Ma C, Horlad H, Ohnishi K, Nakagawa T, Yamada S, Kitada S, Motoshima T, Kamba T, Nakayama T, Fujimoto N, et al. CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma. Med Mol Morphol. 2018;51(1):13–20. https://doi.org/10.1007/s00795-017-0165-8.CrossRefPubMed

54.

Zhou YT, Zheng LY, Wang YJ, Yang L, Xie YT, Panda I, Tian XX, Fang WG. Effect of functional variant rs11466313 on breast cancer susceptibility and TGFB1 promoter activity. Breast Cancer Res Treat. 2020;184(1):237–48. https://doi.org/10.1007/s10549-020-05841-w.CrossRefPubMed

55.

Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev. 2019;99(1):115–60. https://doi.org/10.1152/physrev.00045.CrossRefPubMed

56.

Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y. Prognostic value of immune checkpoint molecules in breast cancer. Biosci Rep. 2020;40(7):BSR20201054. https://doi.org/10.1042/BSR20201054.CrossRefPubMedPubMedCentral

57.

Kosvyra A, Maramis C, Chouvarda I. Developing an integrated genomic profile for cancer patients with the use of NGS data. Emerg Sci J. 2019;3(3):157–67. https://doi.org/10.28991/esj-2019-01178.CrossRef

Title: VWCE as a potential biomarker associated with immune infiltrates in breast cancer
Authors: Qin Huo
Zhenwei Li
Siqi Chen
Juan Wang
Jiaying Li
Ni Xie
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Biomarkers
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-01955-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Signaling pathways of EBV-induced oncogenesis

Identification of the prognostic value of a 2-gene signature of the WNT gene family in UCEC using bioinformatics and real-world data

MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2

LINC00514 upregulates CCDC71L to promote cell proliferation, migration and invasion in triple‐negative breast cancer by sponging miR-6504-5p and miR-3139

Pseudogene HSPA7 is a poor prognostic biomarker in Kidney Renal Clear Cell Carcinoma (KIRC) and correlated with immune infiltrates

CircTP63 promotes hepatocellular carcinoma progression by sponging miR-155-5p and upregulating ZBTB18

Keynote webinar | Spotlight on antibody–drug conjugates in cancer